These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25957782)

  • 1. Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma.
    Morokoff A; Ng W; Gogos A; Kaye AH
    J Clin Neurosci; 2015 Aug; 22(8):1219-26. PubMed ID: 25957782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The landscape of the mesenchymal signature in brain tumours.
    Behnan J; Finocchiaro G; Hanna G
    Brain; 2019 Apr; 142(4):847-866. PubMed ID: 30946477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Advance of molecular subtyping and precise treatment for gliomas].
    Hua W; Mao Y
    Zhonghua Wai Ke Za Zhi; 2017 Jan; 55(1):63-66. PubMed ID: 28056258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular subtypes of glioma identified by genome-wide methylation profiling.
    Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ
    Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas.
    Zhang Q; Xiang W; Yi DY; Xue BZ; Wen WW; Abdelmaksoud A; Xiong NX; Jiang XB; Zhao HY; Fu P
    Stem Cell Res Ther; 2018 Aug; 9(1):228. PubMed ID: 30143053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem cell signature in glioblastoma: therapeutic development for a moving target.
    Nakano I
    J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The stem cell/cancer stem cell marker ALDH1A3 regulates the expression of the survival factor tissue transglutaminase, in mesenchymal glioma stem cells.
    Sullivan KE; Rojas K; Cerione RA; Nakano I; Wilson KF
    Oncotarget; 2017 Apr; 8(14):22325-22343. PubMed ID: 28423611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further understanding of the pathology of glioma: implications for the clinic.
    Camelo-Piragua S; Kesari S
    Expert Rev Neurother; 2016 Sep; 16(9):1055-65. PubMed ID: 27228211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gliomagenesis and the use of neural stem cells in brain tumor treatment.
    Achanta P; Sedora Roman NI; Quiñones-Hinojosa A
    Anticancer Agents Med Chem; 2010 Feb; 10(2):121-30. PubMed ID: 20184546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
    Herting CJ; Chen Z; Pitter KL; Szulzewsky F; Kaffes I; Kaluzova M; Park JC; Cimino PJ; Brennan C; Wang B; Hambardzumyan D
    Glia; 2017 Dec; 65(12):1914-1926. PubMed ID: 28836293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy.
    Vitucci M; Hayes DN; Miller CR
    Br J Cancer; 2011 Feb; 104(4):545-53. PubMed ID: 21119666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and future strategies for treatment of glioma.
    Bush NA; Chang SM; Berger MS
    Neurosurg Rev; 2017 Jan; 40(1):1-14. PubMed ID: 27085859
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Wang Q; Wang Z; Bao Z; Zhang C; Wang Z; Jiang T
    Future Oncol; 2020 Jan; 16(1):4279-4288. PubMed ID: 31797689
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular biology of glioma.
    Marumoto T; Saya H
    Adv Exp Med Biol; 2012; 746():2-11. PubMed ID: 22639155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology and treatment of malignant glioma.
    Prados MD; Levin V
    Semin Oncol; 2000 Jun; 27(3 Suppl 6):1-10. PubMed ID: 10866344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
    Agnihotri S; Aldape KD; Zadeh G
    Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular Classification and Personalized Treatment of Gliomas].
    Sasaki H; Yoshida K
    No Shinkei Geka; 2016 Mar; 44(3):185-201. PubMed ID: 26965060
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular profiling of gliomas: potential therapeutic implications.
    Alentorn A; Duran-Peña A; Pingle SC; Piccioni DE; Idbaih A; Kesari S
    Expert Rev Anticancer Ther; 2015; 15(8):955-62. PubMed ID: 26118895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.